DEFA14A: Silexion Therapeutics Adjourns Shareholder Meeting, Updates Reverse Split Ratio to 1-for-9

Silexion Therapeutics has adjourned its extraordinary general meeting to November 19, 2024, and updated the proposed reverse share split ratio to 1-for-9 to regain Nasdaq compliance.

Summary

• Silexion Therapeutics has postponed its extraordinary general meeting to November 19, 2024.
• The meeting was originally scheduled for November 12, 2024, but was adjourned without conducting any business.
• The primary purpose of the meeting is to approve a reverse share split.
• The initial proposal was for a split between 1-for-10 and 1-for-20, but this has been updated to a fixed ratio of 1-for-9.
• The updated ratio aims to meet Nasdaq's minimum bid price requirement of $1.00 per share and maintain a minimum of 1,100,000 publicly held shares.
• The company believes the reverse split will help in raising capital for preclinical studies and clinical trials.
• The record date for the meeting remains October 22, 2024.

Sentiment

Score: 4

Explanation: The document indicates financial challenges and the need for a reverse stock split to maintain Nasdaq listing, which is generally viewed negatively by investors. However, the company is taking steps to address these issues and continue its research.

Positives

• The updated reverse share split ratio is designed to ensure continued listing on the Nasdaq Global Market.
• The company anticipates that the reverse split will facilitate future capital raising efforts.
• Silexion is actively addressing its compliance issues with Nasdaq.

Negatives

• The extraordinary general meeting was adjourned without conducting any business, indicating a potential lack of preparedness or shareholder support.
• The need for a reverse share split suggests the company's share price is below the required minimum.

Risks

• There is a risk that shareholders may not approve the proposed reverse share split.
• The reverse share split may not result in a sustained increase in the share price.
• The company may not be able to raise sufficient capital even after the reverse split.
• The company's future success depends on the outcome of its preclinical studies and clinical trials.

Future Outlook

The company expects the reverse share split to help it regain compliance with Nasdaq listing rules and facilitate future capital raising. The company is focused on advancing its preclinical studies and clinical trials.

Management Comments

• The board of directors decided to update the reverse share split ratio to 1-for-9.
• Mirit Horenshtein Hadar, the company's CFO, can be contacted for questions or assistance with voting.

Industry Context

Silexion is a clinical-stage oncology-focused biotechnology company developing RNAi therapies, which is a competitive and innovative area within the biotech industry. The company's focus on KRAS mutations aligns with a significant unmet need in cancer treatment.

Comparison to Industry Standards

• Many biotech companies, especially those in early clinical stages, face challenges in maintaining Nasdaq listing compliance, often resorting to reverse stock splits.
• Companies like Silexion, focusing on novel therapies such as RNAi, are competing with larger pharmaceutical companies and other biotech firms in the oncology space.
• The need for a reverse split is not uncommon for companies with low share prices, but it can be a sign of financial challenges and may impact investor confidence.

Stakeholder Impact

• Shareholders are directly impacted by the proposed reverse share split and the potential for share price dilution.
• The company's ability to raise capital will impact its ability to fund research and development, which affects employees and future patients.
• The company's compliance with Nasdaq listing rules is important for maintaining investor confidence.

Next Steps

• Shareholders are urged to vote on the updated reverse share split proposal at the rescheduled Extraordinary Meeting on November 19, 2024.
• The company will continue to work towards regaining compliance with Nasdaq listing rules.
• Silexion will continue to advance its preclinical studies and clinical trials.

Key Dates

Keywords

reverse share split, Nasdaq compliance, extraordinary general meeting, shareholder vote, capital raising, minimum bid price, RNAi therapies, oncology, KRAS mutations, clinical trials